PATRICK HWU, M.D.
Osteopathic Medicine at Holcombe Blvd, Houston, TX

7419957, Sep 2, 2008

Aug 22, 2002

10/486989

Patrick Hwu - Houston TX, US
Rejean LaPointe - Laval, CA
Steven A. Rosenberg - Potomac MD, US
Maria Parkhurst - Ellicott City MD, US

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

A61K 38/00, A61K 39/395

514 13, 530326

Immunogenic peptides of a melanoma antigen recognized by T cells, designated gp100, bioassays using the peptides to diagnose, assess or prognose a mammal afflicted with cancer, more specifically melanoma or metastatic melanoma, and use of the proteins and peptides as immunogens to inhibit, prevent or treat melanoma.

2013030, Nov 14, 2013

Sep 30, 2011

13/876198

Laszlo Radvanyi - Houston TX, US
Patrick Hwu - Houston TX, US
Chantale Bernatchez - Spring TX, US

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

C12N 5/0783

424 9371, 435325

BTLA-positive (“BTLA+”) lymphocyte signaling drives T cells and kills tumors. BTLA functions as a positive modulator of anti-tumor (anti-melanoma) T cell responses, The BTLA+ T cell responds against tumor or cancer cells, and, in cancer patients respond better to IL-2 than BTLA-negative cells. Hence, the BTLA-positive T cell in cancers is a positive marker for selection of enriched anti-tumor-cancer reactive T cells and can be used or applied for adoptive T-cell therapy or for therapeutic purposes.

7749967, Jul 6, 2010

Aug 21, 2008

12/195809

Patrick Hwu - Houston TX, US
Rejean LaPointe - Laval, CA
Steven A. Rosenberg - Potomac MD, US
Maria Parkhurst - Ellicott City MD, US

The United States of America as represented by the Department of Health and Human Services. - Washington DC

A61K 38/00, C07K 5/00

514 13, 530326, 435 723, 435 721

Immunogenic peptides of a melanoma antigen recognized by T cells, designated gp100, bioassays using the peptides to diagnose, assess or prognose a mammal afflicted with cancer, more specifically melanoma or metastatic melanoma, and use of the proteins and peptides as immunogens to inhibit, prevent or treat melanoma.

8252545, Aug 28, 2012

May 19, 2010

12/782858

Patrick Hwu - Houston TX, US
Rejean LaPointe - Laval, CA
Steven A. Rosenberg - Potomac MD, US
Maria Parkhurst - Ellicott City MD, US

The United States of America, as represented by the Secretary Department of Health and Human Services - Washington DC

C07K 16/00, A61K 38/00

435 723, 514 192, 530324, 4241851

Immunogenic peptides of a melanoma antigen recognized by T cells, designated gp100, bioassays using the peptides to diagnose, assess or prognose a mammal afflicted with cancer, more specifically melanoma or metastatic melanoma, and use of the proteins and peptides as immunogens to inhibit, prevent or treat melanoma.

2010013, Jun 3, 2010

Jan 4, 2010

12/651858

Patrick Hwu - Houston TX, US
Gang Wang - Montgomery Village MD, US
Warren Leonard - Bethesda MD, US
Rosanne Spolski - Ellicott City MD, US
Katsutoshi Ozaki - Tochigi, JP

AND HUMAN SERVICES - BETHESDA MD

A61K 38/20, A61K 31/7088, A61P 37/00

424 852, 514 44 R

A method of treating and/or preventing cancer in a subject, preferably mammalian, more preferably human, by administering in an effective amount IL-21 polypeptide, polynucleotide, vector comprising an IL-21 nucleic acid sequence encoding an IL-21 polypeptide, variants, and fragments thereof, thereby acting as an anti-cancer agent by reducing, ameliorating, and/or eliminating the cancer; and a method of treating and/or preventing cancer in a subject by co-administering the IL-21 polypeptide, polynucleotide, IL-21 vector, variant, and fragments thereof, with an immunotherapeutic and/or chemotherapeutic agent for the treatment and/or prevention of cancer in a subject.

2012030, Dec 6, 2012

Feb 3, 2011

13/577207

Dapeng Zhou - Houston TX, US
Chun Li - Missouri City TX, US
Patrick Hwu - Houston TX, US

A61K 38/02, A61P 35/00, C07K 14/00

514 193, 530358

Nanoconstructs having three components: (1) biodegradable nanopolymers and nanoparticles, (2) immunodrugs such as CpG, and a (3) tumor binding device, which are actively targeted to tumor cells such as melanoma cells through receptor-mediated uptake and methods of using the same are described. Antitumor immunity is further enhanced by combination of PG-CpG nanoconstructs with agonists of positive costimulatory signals and inhibitors of negative immune regulatory signals.

2010015, Jun 24, 2010

Mar 2, 2010

12/715829

Patrick Hwu - Houston TX, US
Michael H. Kershaw - Victoria, AU
Steven A. Rosenberg - Potomac MD, US

The U.S.A. as represented by the Secretary, Dept. of Health and Human Services - Bethesda MD

A61K 35/26, C12N 5/00, C12N 5/071

424 9321, 435325, 4353723

The present invention relates to preventive, therapeutic, and diagnostic compositions and methods employing lymphocytes having T-cell receptors and chimeric receptors. In particular, the invention relates to pre-selected dual-specificity lymphocytes having endogenous T-cell receptors and chimeric T-cell receptors that recognize a strong antigen and tumor associated antigens where the pre-selected population of adoptively transferred lymphocytes is activated by in vivo immunization, thereby increasing the effectiveness of adoptive immunotherapy.